

FDA approves odomzo for recurring basal cell carcinoma

July 25 2015



Odomzo (sonidegib) has been approved by the U.S. Food and Drug Administration to treat locally advanced basal cell carcinoma that has returned despite surgery or radiation. The treatment is sanctioned for people who are not candidates for additional surgery or radiation.

(HealthDay)—Odomzo (sonidegib) has been approved by the U.S. Food and Drug Administration to treat patients with locally advanced basal cell carcinoma that has returned despite surgery or radiation, or who are not candidates for additional surgery or radiation.

The once-daily pill is designed to inhibit the Hedgehog pathway. The drug was evaluated in a clinical study involving 66 people. Fifty-eight percent of people treated with 200 mg of Odomzo had their tumors shrink or disappear, the FDA said. The most common side effects included [muscle spasms](#), alopecia, dysgeusia, fatigue, nausea, myalgia, diarrhea, and weight loss. More serious musculoskeletal issues also are possible.

The drug's label includes a boxed warning that it may cause death or severe birth defects in a growing fetus. Women who may become pregnant should verify pregnancy status before taking the drug. And both males and females who take Odomzo are advised to use contraception, the agency said.

"Thanks to a better understanding of the Hedgehog pathway, the FDA has now approved two drugs for the treatment of basal cell carcinoma just in the last three years," Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in a statement. Erivedge (vismodegib) was approved in 2012 to treat locally advanced and metastatic [basal cell carcinoma](#)

Odomzo is marketed by Novartis, based in East Hanover, N.J.

More information: [More Information](#)

[Health News](#) Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: FDA approves odomzo for recurring basal cell carcinoma (2015, July 25) retrieved 17 April 2024 from <https://medicalxpress.com/news/2015-07-fda-odomzo-recurring-basal-cell.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.